Annual report
2784.TEDINET S100R438
Period2022-04-01 → 2023-03-31
Filed2023-06-27
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.70T | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥2.59T | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥2.61T | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.70T | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.64T | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥30.1bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥29.1bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥32.8bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥32.6bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥31.9bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥57.2bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥55.1bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥38.6bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥48.2bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥25.8bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥32.2bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥24.5bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥40.3bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥41.7bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥25.8bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | ¥32.2bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥1.34T | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥1.30T | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥1.32T | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.35T | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.34T | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥851.5bn | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥832.2bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥488.3bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥471.8bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥490.0bn | at 2021-03-31d | Cons. | Net assets |
| Net assets / equity | ¥474.9bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥442.1bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥160.1bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥180.4bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥158.8bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥179.1bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥169.1bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥209.3bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥205.1bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥13.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥36.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥21.2bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥33.8bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥46.9bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥20.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥2.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥4.7bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥17.0bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥12.9bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥12.9bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥29.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥14.5bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥12.6bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥24.9bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥127.42 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥153.57 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥115.75 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥190.26 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥195.91 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥2,411.89 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,330.36 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,313.66 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,237.89 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,083.03 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 36.4% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.2% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.2% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.0% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.9% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 5.4% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.7% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.1% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.8% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.5% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 11,772 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 11,925 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 12,045 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 12,074 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 12,076 | at 2019-03-31d | Cons. | Number of employees |
| Revenue | ¥22.2bn | 2022-04-01 → 2023-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥17.2bn | 2021-04-01 → 2022-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥25.3bn | 2020-04-01 → 2021-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥26.1bn | 2019-04-01 → 2020-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥22.0bn | 2018-04-01 → 2019-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥20.1bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥15.2bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥20.3bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥15.4bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥23.7bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥24.5bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥20.2bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥20.3bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥13.7bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥20.4bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥13.6bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥23.9bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥22.3bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥20.2bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥271.9bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥265.3bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥277.5bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥260.4bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥248.3bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥15.1bn | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥17.7bn | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥256.8bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥247.6bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥261.3bn | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥248.3bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥236.1bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥24.2bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥21.0bn | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥100.79 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥64.88 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥112.78 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥105.2 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥94.74 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥57 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥54 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥53 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥48 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,269.01 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,223.58 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,234.61 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,173.2 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,115.63 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 94.4% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 93.3% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 94.2% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 95.4% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 95.1% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 8.1% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.3% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.4% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.2% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.5% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 202,840,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 235,017,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 235,017,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 235,017,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 235,017,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 47 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 44 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 38 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 38 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 38 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 85
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥2.0bn |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥2.3bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥31.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥31.2bn |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥24.7bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | ¥315m |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥8.5bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥6.2bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | employees | at 2023-03-31 | 8680 pure |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥2.40T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥2.38T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥16.8bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment assets | at 2023-03-31 | ¥1.14T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥27.0bn |
| Manufacturing Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥2.0bn |
| Manufacturing Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥3.6bn |
| Manufacturing Businessreportable segment | employees | at 2023-03-31 | 1383 pure |
| Manufacturing Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥49.0bn |
| Manufacturing Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥35.2bn |
| Manufacturing Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥13.9bn |
| Manufacturing Businessreportable segment | segment assets | at 2023-03-31 | ¥70.1bn |
| Manufacturing Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥420m |
| Medical Related Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥912m |
| Medical Related Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥396m |
| Medical Related Businessreportable segment | employees | at 2023-03-31 | 1187 pure |
| Medical Related Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥36.2bn |
| Medical Related Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥36.2bn |
| Medical Related Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥0 |
| Medical Related Businessreportable segment | segment assets | at 2023-03-31 | ¥16.3bn |
| Medical Related Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥330m |
| Self Medication Products Wholesaling Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥251m |
| Self Medication Products Wholesaling Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥326m |
| Self Medication Products Wholesaling Businessreportable segment | employees | at 2023-03-31 | 398 pure |
| Self Medication Products Wholesaling Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥246.7bn |
| Self Medication Products Wholesaling Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥246.2bn |
| Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥527m |
| Self Medication Products Wholesaling Businessreportable segment | segment assets | at 2023-03-31 | ¥89.7bn |
| Self Medication Products Wholesaling Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥2.1bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-04-01 → 2023-03-31 | ¥11.7bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-04-01 → 2023-03-31 | ¥10.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥2.73T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥2.70T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥31.2bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-03-31 | ¥1.32T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥29.8bn |
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | ¥2.1bn |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥2.1bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥29.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥29.1bn |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥15.5bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | ¥332m |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥9.6bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥6.0bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥2.29T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥2.27T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥15.7bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment assets | at 2022-03-31 | ¥1.12T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥24.8bn |
| Manufacturing Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥3.9bn |
| Manufacturing Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥3.3bn |
| Manufacturing Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥47.4bn |
| Manufacturing Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥34.6bn |
| Manufacturing Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥12.8bn |
| Manufacturing Businessreportable segment | segment assets | at 2022-03-31 | ¥70.5bn |
| Manufacturing Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥1.9bn |
| Medical Related Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥426m |
| Medical Related Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥387m |
| Medical Related Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥34.5bn |
| Medical Related Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥34.5bn |
| Medical Related Businessreportable segment | segment assets | at 2022-03-31 | ¥16.7bn |
| Medical Related Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥183m |
| Self Medication Products Wholesaling Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥306m |
| Self Medication Products Wholesaling Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥357m |
| Self Medication Products Wholesaling Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥244.8bn |
| Self Medication Products Wholesaling Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥244.2bn |
| Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥610m |
| Self Medication Products Wholesaling Businessreportable segment | segment assets | at 2022-03-31 | ¥83.0bn |
| Self Medication Products Wholesaling Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥1.9bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-04-01 → 2022-03-31 | ¥14.2bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-04-01 → 2022-03-31 | ¥10.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2022-03-31 | ¥2.61T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2022-03-31 | ¥2.59T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥29.1bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥1.29T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2022-03-31 | ¥28.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,066
| Item | Context | Value | Unit |
|---|---|---|---|
| Disposal of treasury stock | CurrentYearDuration_NonConsolidatedMember | 0 | JPY |
| Retirement of treasury stock | CurrentYearDuration_NonConsolidatedMember | － | JPY |
| Net changes of items other than shareholders equity | CurrentYearDuration_NonConsolidatedMember_ValuationDifferenceOnAvailableForSaleSecuritiesMember | -65000000 | JPY |
| Net changes of items other than shareholders equity | CurrentYearDuration_NonConsolidatedMember_ValuationAndTranslationAdjustmentsMember | -65000000 | JPY |
| Net changes of items other than shareholders equity | CurrentYearDuration_NonConsolidatedMember | -65000000 | JPY |
| Total changes of items during the period | CurrentYearDuration_NonConsolidatedMember_ValuationDifferenceOnAvailableForSaleSecuritiesMember | -65000000 | JPY |
| Total changes of items during the period | CurrentYearDuration_NonConsolidatedMember_ValuationAndTranslationAdjustmentsMember | -65000000 | JPY |
| Total changes of items during the period | CurrentYearDuration_NonConsolidatedMember | 9190000000 | JPY |
| Net assets | CurrentYearInstant_NonConsolidatedMember_ValuationDifferenceOnAvailableForSaleSecuritiesMember | 1886000000 | JPY |
| Net assets | CurrentYearInstant_NonConsolidatedMember_ValuationAndTranslationAdjustmentsMember | 1886000000 | JPY |
| Net assets | CurrentYearInstant_NonConsolidatedMember | 256806000000 | JPY |
| Directors compensations sga | Prior1YearDuration_NonConsolidatedMember | 322000000 | JPY |
| Directors compensations sga | CurrentYearDuration_NonConsolidatedMember | 303000000 | JPY |
| Salaries and allowances sga | Prior1YearDuration_NonConsolidatedMember | 387000000 | JPY |
| Salaries and allowances sga | CurrentYearDuration_NonConsolidatedMember | 364000000 | JPY |
| Provision for bonuses sga | Prior1YearDuration_NonConsolidatedMember | 76000000 | JPY |
| Provision for bonuses sga | CurrentYearDuration_NonConsolidatedMember | 71000000 | JPY |
| Provision for directors bonuses sga | Prior1YearDuration_NonConsolidatedMember | 55000000 | JPY |
| Provision for directors bonuses sga | CurrentYearDuration_NonConsolidatedMember | 55000000 | JPY |
| Commission fee sga | Prior1YearDuration_NonConsolidatedMember | 357000000 | JPY |
| Commission fee sga | CurrentYearDuration_NonConsolidatedMember | 369000000 | JPY |
| Rent expenses sga | Prior1YearDuration_NonConsolidatedMember | 258000000 | JPY |
| Rent expenses sga | CurrentYearDuration_NonConsolidatedMember | 255000000 | JPY |
| Depreciation sga | Prior1YearDuration_NonConsolidatedMember | 9000000 | JPY |
| Depreciation sga | CurrentYearDuration_NonConsolidatedMember | 21000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)有価証券報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2023-06-27 | |
| Fiscal year cover page | FilingDateInstant | Original text (Japanese)第20期(自 2022年４月１日 至 2023年３月31日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)アルフレッサ ホールディングス株式会社 | |
| Company name in english cover page | FilingDateInstant | Alfresa Holdings Corporation | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 荒川 隆治 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都千代田区大手町一丁目１番３号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 03-5219-5100 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)代表取締役 副社長社長補佐 総務・財務企画・コーポレートコミュニケーション・コンプライアンス担当岸田 誠一 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都千代田区大手町一丁目１番３号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 03-5219-5100 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)代表取締役 副社長社長補佐 総務・財務企画・コーポレートコミュニケーション・コンプライアンス担当岸田 誠一 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E02962 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 27840 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)アルフレッサ ホールディングス株式会社 | |
| Filer name in english | FilingDateInstant | Alfresa Holdings Corporation | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第三号様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |